118 related articles for article (PubMed ID: 19644534)
1. Targeted therapies: GIST adjuvant therapy-some answers and more questions.
Eisenberg B
Nat Rev Clin Oncol; 2009 Aug; 6(8):441-2. PubMed ID: 19644534
[No Abstract] [Full Text] [Related]
2. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
3. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
Cao H; Wang M
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):812-819. PubMed ID: 31550818
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting.
Agaimy A
Int J Clin Exp Pathol; 2010 May; 3(5):461-71. PubMed ID: 20606727
[TBL] [Abstract][Full Text] [Related]
5. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
6. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
8. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in gastrointestinal stromal tumour management.
Blay JY
Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
[TBL] [Abstract][Full Text] [Related]
10. Expanding the boundaries of clinical practice: building on experience with targeted therapies.
Sternberg CN
Ann Oncol; 2009 May; 20 Suppl 1():i1-6. PubMed ID: 19430002
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
13. Managing GIST in the imatinib era: optimization of adjuvant therapy.
Trent JC; Subramanian MP
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
[TBL] [Abstract][Full Text] [Related]
14. [Gastrointestinal stromal tumors (GIST): at the forefront of targeted therapies].
Emile JF
Med Sci (Paris); 2013; 29(6-7):630-6. PubMed ID: 23859518
[TBL] [Abstract][Full Text] [Related]
15. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
16. [Contemporary treatment of gastrointestinal stromal tumors].
Nishida T
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1639-44. PubMed ID: 18931562
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
[TBL] [Abstract][Full Text] [Related]
18. [Significance of circulating tumor cell monitoring in targeted therapy for gastrointestinal stromal tumors].
Fan JB; Zhi XF; Chen SS; Zhu JW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):789-795. PubMed ID: 34530560
[No Abstract] [Full Text] [Related]
19. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
Blay JY
Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of gastrointestinal stromal tumors--a comprehensive view of the surgeon].
Fiala L; Šefr R; Kocáková I; Pacal M
Rozhl Chir; 2015 May; 94(5):189-92. PubMed ID: 26112683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
